Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes and significantly enhances their quality of life. Additionally, Feldan is advancing a pulmonary program that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases.
Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, "At Zydus, we are committed towards advancing the development of novel therapeutics to addressing critical gaps in healthcare through innovation. We are pleased to support Feldan in exploring a potentially safe and targeted option for patients with dermatological and pulmonary disease and help them lead a better quality of life."
Jay Kothari , Director of Zynext Ventures, highlighted, "Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive innovations we aim to add to our portfolio."
"This partnership with Zynext Ventures marks an exciting step forward in our commitment to improve patients' quality of life and address critical drug delivery challenges," said François- Thomas Michaud , CEO of Feldan Therapeutics. "With Zynext Ventures' strategic expertise and shared dedication to innovation, we are well-positioned to accelerate the development of next-generation therapies."
About Zynext Ventures
Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients.
For more details visit: www.zynextventures.com
About Zydus
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: www.zyduslife.com.
About Feldan
Feldan is a clinical-stage pharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics. Its proprietary peptide-based technology, the Feldan Shuttle, enables the safe and efficient delivery of antisense oligonucleotides into cells, unlocking the potential for a new generation of therapies. Feldan's lead product for BCC (FLD-103) is in a Phase 1/2a clinical trial, and the company's pipeline expansion is focused on skin and lung diseases.
SOURCE Zydus Lifesciences Ltd
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
11-07-2025
- Cision Canada
Class B Holdings Limited Updates Reporting on Empire Shares Pursuant to National Instrument 62-103
STELLARTON, NS, July 11, 2025 /CNW/ - This press release is being disseminated as required by National Instrument 62-103 - The Early Warning System and Related Take-Over Bids and Insider Reporting Issuers ("NI 62-103") in connection with the filing of an early warning report by Class B Holdings Limited ("CBHL") as a result of its acquisition of Class B common shares of Empire Company Limited ("Class B Shares") in a private transaction. CBHL, beneficially owned by three branches of the Sobey family, confirmed today that it has acquired 90,000 Class B Shares at a price of $54.40 per share, being approximately 0.09% of the outstanding Class B Shares. The acquisition results in an aggregate increase of 2.03% of the outstanding Class B Shares since CBHL's early warning report on December 28, 2017. Prior to the acquisition, CBHL beneficially held an aggregate of 92,833,092 Class B Shares representing 94.59% of the outstanding Class B Shares. Following acquisition, CBHL beneficially hold an aggregate of 92,923,092 Class B Shares representing 94.69% of the outstanding Class B Shares. CBHL, together with its shareholders and their affiliates, own or control 92,941,170 Class B Shares representing approximately 94.71% of the outstanding Class B common shares. CBHL, its shareholders and their affiliates have no intention to undertake any other transactions relating to his ownership of Empire. However, subject to regulatory limitations, they may acquire or continue to hold Empire shares in the normal course of their investment activities.
Cision Canada
03-07-2025
- Cision Canada
Aura Minerals Announces Filing of Early Warning Report Regarding Altamira Gold Corp.
ROAD TOWN, British Virgin Islands, July 3, 2025 /CNW/ - Aura Minerals Inc. (TSX: ORA) (B3: AURA33) and (OTCQX: ORAAF) (" Aura" or the " Company") announced that it has entered into a subscription agreement (the " Subscription Agreement") with Altamira Gold Corp. (the " Issuer" or " Altamira") pursuant to which it acquired, in a non-brokered private placement (the " Private Placement"), 6,000,000 units of the Issuer (" Units") at a price of C$0.10 per Unit for an aggregate purchase price of C$600,000. Each Unit consists of one common share (each, a " Share") and one-half of one common share purchase warrant (each, a " Warrant") of the Issuer. Each Warrant is exercisable to acquire one Share of the Issuer at an exercise price of C$0.15 per Share until June 30, 2027. Prior to entering into the Subscription Agreement, Aura held 24,000,000 Shares and 24,000,000 Warrants, representing approximately 11.3% of the issued and outstanding Shares on a non-diluted basis and approximately 20.3% of the issued and outstanding Shares on a fully diluted basis. Immediately upon the closing of the Private Placement, Aura holds 30,000,000 Shares and 27,000,000 Warrants, representing approximately 11.3% of the issued and outstanding Shares on a non-diluted basis and approximately 19.5% of the issued and outstanding Shares on a fully diluted basis. Aura acquired the Units directly from the Issuer in the Private Placement and not through the facilities of any stock exchange or other marketplace. Aura acquired the Units for investment purposes given the exploration potential of Altamira. Aura may, from time to time and depending on the market and other conditions, acquire additional securities of the Issuer, dispose of some or all of the existing or additional securities it holds or will hold, or may continue to hold its current position, depending on market conditions, reformulation of plans and/or relevant factors. For additional information on Altamira, readers are encouraged to visit: Altamira's head office is located at Suite 1500 409 Granville St., Vancouver, British Columbia, V6C 1T2. This press release is issued pursuant to National Instrument 62-103 — The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which also require a report to be filed with regulatory authorities in each of the jurisdictions containing additional information with respect to the foregoing matters (the " Early Warning Report"). A copy of the Early Warning Report will be filed with the Issuer's documents on the SEDAR+ website at About Aura 360° Mining Aura is focused on mining in complete terms – thinking holistically about how its business impacts and benefits every one of our stakeholders: our company, our shareholders, our employees, and the countries and communities we serve. We call this 360° Mining. Aura is a mid-tier gold and copper production company focused on operating and developing gold and base metal projects in the Americas. The Company has 5 operating mines including the Aranzazu copper-gold-silver mine in Mexico, the Apoena, Almas and Borborema gold mines in Brazil, and the Minosa mine in Honduras. The Company's development projects include Cerro Blanco in Guatemala and Matupá both in Brazil. Aura has unmatched exploration potential owning over 630,000 hectares of mineral rights and is currently advancing multiple near-mine and regional targets along with the Carajas (Serra da Estrela) copper project in the prolific Carajás region of Brazil Forward-Looking Information This press release contains "forward-looking information" and "forward-looking statements", as defined in applicable securities laws (collectively, "forward-looking statements") which may include, but is not limited to, statements with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, including the Company acquiring or disposing the Issuer's securities and the filing of the Early Warning Report. Often, but not always, forward-looking statements can be identified by the use of words and phrases such as "plans," "expects," "is expected," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates," or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved. Known and unknown risks, uncertainties and other factors, many of which are beyond the Company's ability to predict or control, could cause actual results to differ materially from those contained in the forward-looking statements. Specific reference is made to the most recent Annual Information Form on file with certain Canadian provincial securities regulatory authorities for a discussion of some of the factors underlying forward-looking statements, which include, without limitation, volatility in the prices of gold, copper and certain other commodities, changes in debt and equity markets, the uncertainties involved in interpreting geological data, increases in costs, environmental compliance and changes in environmental legislation and regulation, interest rate and exchange rate fluctuations, general economic conditions and other risks involved in the mineral exploration and development industry. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect the forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements whether as a result of new information or future events or otherwise, except as may be required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements.
Cision Canada
30-06-2025
- Cision Canada
Frontenac Mortgage Investment Corporation Announces Failure-To-File Cease Trade Order, Provides Update on Outstanding Filings, Pro Rata Redemption Plan, and Annual Meeting
OTTAWA, ON, June 30, 2025 /CNW/ - Frontenac Mortgage Investment Corporation (" FMIC" or the " Company") announces that further to its press releases of May 12, 2025 and June 19, 2025, the Company continues to work diligently with MNP LLP (" MNP"), its external auditors, to complete the audit of the Company's annual financial statements for the year ended December 31, 2024. MNP has confirmed to the Company and the Ontario Securities Commission (the " OSC") that they expect to complete their work to permit the Company to file the financial statements, management's discussion and analysis, and related chief executive officer and chief financial officer certificates (the " Annual Filings") by July 29, 2025, and not July 18, 2025, as previously advised by MNP. There has been no change to the Company's expectation to file its outstanding unaudited interim financial statements for the three months ended March 31, 2025, management's discussion and analysis, and related chief executive officer and chief financial officer certificates (the " Interim Filings") concurrently with or as soon as practicable after its Annual Filings. Given the further delay in filing, the OSC has advised the Company that it will revoke the management cease-trade order previously issued to the Company and issue a failure-to-file cease trade order (" FFCTO") under Multilateral Instrument 11-103 – Failure-to-File Cease Trade Orders in Multiple Jurisdictions against the Company, effective July 3, 2025. The Company expects that the FFCTO will remain in effect until the Annual Filings and Interim Filings are filed. If and when issued, the FFCTO will prohibit all trading in common shares of the Company. Provided that the Annual Filings and Interim Filings are made within 90 days of the date of the FFCTO, such filings would constitute an application to revoke the FFCTO. As a result of the delay in finalizing the Company's financial statements, the Company has delayed the redemption of common shares and related distribution that was anticipated to be completed in Q2 2025 pursuant to the Pro Rata Redemption Plan outlined in the Company's management information circular dated October 31, 2024. The Company expects to complete the redemption planned that was anticipated for Q2 2025 as soon as reasonably practicable after the filing of the Annual Filings and Interim Filings and the revocation of the FFCTO by the OSC. The Company remains committed to carrying out its Pro Rata Redemption Plan in a manner that is transparent, responsible, and aligned with the best interests of its shareholders. FMIC also announces that its annual meeting of shareholders will be held on August 28, 2025 (the " Meeting"). Shareholders of record on July 18, 2025, will be entitled to receive formal notice of and vote at the Meeting. Proxy materials in respect of the Meeting will be sent to shareholders in due course. Additional information about the Company is available under FMIC's profile on SEDAR+ at Forward-Looking Statements This press release contains certain forward-looking statements and forward-looking information (collectively referred to herein as " forward-looking statements") within the meaning of applicable Canadian securities laws, which may include, but are not limited to, information and statements in respect of the time by which MNP expects to complete its audit of the Company's annual financial statements for the year ended December 31, 2024; timing of the filing of the Annual Filings and Interim Filings, and the issuance and revocation of the FFCTO by the OSC; the redemption of outstanding common shares pursuant to the Pro Rata Redemption Plan, and the anticipated timing of future redemptions; the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "may", "will", "project", "should" or similar words, including negatives thereof, suggesting future outcomes. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors beyond FMIC's ability to predict or control, which may cause actual events, results, performance, or achievements of FMIC to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein. Forward-looking statements are not a guarantee of future performance. Although FMIC believes that any forward-looking statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that any such forward-looking statements will prove to be accurate. Actual results may vary, and vary materially, from those expressed or implied by the forward-looking statements herein. Accordingly readers are advised to rely on their own evaluation of the risks and uncertainties inherent in forward-looking statements herein and should not place undue reliance upon such forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Any forward-looking statements herein are made only as of the date hereof, and except as required by applicable laws, FMIC assumes no obligation and disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking statements herein, whether as a result of new information, future events or results, or otherwise.
